Capricor Therapeutics: Buying Opportunity Following FDA’s CRL (CAPR)
This article was written byFollowBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven...
Biogen: Competing With Eli Lilly’s Kisunla, Safety Gives Market Edge (NASDAQ:BIIB)
S&P 500 2026 Outlook: Why The Fed Is The Whole Story (SP500)
BME: Attractive Discount With Steady Monthly Distribution (NYSE:BME)
Pinterest: I’m Giving Up On This Company (Rating Downgrade) (NYSE:PINS)
Be The Bank: I Am Locking In 7% Yields From Corporate And Municipal Borrowers Now